QCM
BBC icon

Quantinno Capital Management’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Quantinno Capital Management’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Buy
23,009
+3,626
+19% +$162K ﹤0.01% 2411
2026
Q1 		$807K Buy
+19,383
New +$794K ﹤0.01% 2350

Other funds holding BBC

KCP
Kera Capital Partners San Jose, California $1.04B AUM 52.56% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
MCM
Militia Capital Management Austin, Texas $3.37B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Quantinno Capital Management's BBC Position: Q2 2026 in Review

Quantinno Capital Management increased its Virtus Biotech Clinical Trials ETF (BBC) stake by 19% in Q2 2026, buying an estimated $162K and bringing the position to 23,009 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2411.

Quantinno Capital Management first reported a position in BBC in Q1 2026 and has held it in 2 quarters since. 20 funds tracked by Wall St. Rank hold BBC as of Q2 2026.

  • Quantinno Capital Management held 23,009 shares of Virtus Biotech Clinical Trials ETF worth $1.21M as of Q2 2026.
  • Quantinno Capital Management bought 3,626 Virtus Biotech Clinical Trials ETF shares in Q2 2026, an estimated $162K.
  • Virtus Biotech Clinical Trials ETF made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2411 holding.
  • Quantinno Capital Management first reported a position in Virtus Biotech Clinical Trials ETF in Q1 2026 and has held it in 2 quarters since.
  • 20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.